CCM
IPSC icon

CAAS Capital Management’s Century Therapeutics IPSC Stock Holding History

CAAS Capital Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30,000
Closed -$755K – 954
2021
Q3 		$755K Hold
30,000
– – 0.02% 545
2021
Q2 		$880K Buy
+30,000
New +$761K 0.01% 615

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAAS Capital Management's IPSC Position: Q4 2021 in Review

CAAS Capital Management sold out of Century Therapeutics (IPSC) in Q4 2021, closing a stake of 30,000 shares — an estimated $755K sold.

CAAS Capital Management first reported a position in IPSC in Q2 2021 and held it in 2 quarters. The position peaked at $880K in Q2 2021. 50 funds tracked by Wall St. Rank hold IPSC as of Q4 2021.

  • CAAS Capital Management reported no remaining Century Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 30,000 Century Therapeutics shares in Q4 2021, an estimated $755K.
  • CAAS Capital Management first reported a position in Century Therapeutics in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's Century Therapeutics position peaked at $880K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.